APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES

Abstract

financing of rare disease drugs remains a serious problem for both foreign countries and our country. A limited budget for treatment of such patients determines significant difficulties for its distribution as part of drug supply to rare disease patients. The introduction of multiple-criteria analysis for identifying priority areas for financing diseases can be considered as one of the approaches to increase objectivity and transparency of decisions in the area of rare diseases. The main advantage of multiple-criteria analysis is the comprehensiveness of decisions: this type of analysis can provide consideration of disease severity and treatment efficacy. In 2014, a pilot study was conducted in the Russian Federation which involved 85 experts in various fields of medicine (clinical medicine, health financing, health management, scientific activity), which demonstrated that, from the point of view of experts, the characteristics of treatment are more important for identification of rare disease funding priority than the characteristics of the disease itself.

Keywords

• rare diseases
• multiple-criteria decision analysis
• orphan drugs
• making decisions